Stock NWRN NEWRON PHARMACEUTICALS S.P.A.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Newron Pharmaceuticals S.p.A.

Equities

NWRN

IT0004147952

Pharmaceuticals

Delayed Swiss Exchange
Other stock markets
 07:57:11 2024-05-03 am EDT 		5-day change 1st Jan Change
8.7 CHF +4.69% Intraday chart for Newron Pharmaceuticals S.p.A. +24.29% +75.76%
Apr. 30 Newron Pharmaceuticals S.p.A. Announces Positive Top-line Results From Potentially Pivotal Phase II/III Study 008A With Evenamide in Schizophrenia Patients CI
Apr. 17 Newron Pharmaceuticals Appoints Margarita Chavez as Independent Board Member CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 104.4 35.36 27.92 27.93 95.03 158.6 - -
Enterprise Value (EV) 1 81.95 29.79 27.92 60.17 95.03 187.7 160.6 158.6
P/E ratio -5.18 x -1.68 x -1.86 x -1.6 x -5.85 x 10.9 x 36.5 x 5.64 x
Yield - - - - - - - -
Capitalization / Revenue 14.8 x 6.73 x 4.85 x 4.58 x 10.5 x 4.41 x 6.11 x 3.05 x
EV / Revenue 11.6 x 5.67 x 4.85 x 9.87 x 10.5 x 5.22 x 6.19 x 3.05 x
EV / EBITDA -3.96 x -1.67 x -2.3 x -4.59 x - 9.98 x 18 x 4.29 x
EV / FCF -3.68 x -1.91 x - -5.42 x - 5.21 x 13.4 x 3.69 x
FCF Yield -27.2% -52.4% - -18.5% - 19.2% 7.47% 27.1%
Price to Book - 2.05 x - -1.99 x - -12.4 x 23.4 x -
Nbr of stocks (in thousands) 17,845 17,845 17,845 17,845 17,845 18,632 - -
Reference price 2 5.848 1.982 1.565 1.565 5.325 8.511 8.511 8.511
Announcement Date 3/5/20 3/16/21 3/15/22 3/14/23 3/19/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 7.038 5.258 5.762 6.094 9.057 35.98 25.95 52
EBITDA 1 -20.69 -17.85 -12.15 -13.1 - 18.81 8.931 37
EBIT 1 -20.9 -18.07 -12.36 -13.3 -11.63 18.43 8.891 37
Operating Margin -296.95% -343.59% -214.46% -218.28% -128.4% 51.22% 34.26% 71.15%
Earnings before Tax (EBT) 1 -20.16 -19.62 -14.88 -17.47 - 14.73 5.067 35
Net income 1 -20.21 -21 -14.9 -17.49 -16.22 7.6 4.066 27
Net margin -287.11% -399.35% -258.61% -287.05% -179.13% 21.12% 15.67% 51.92%
EPS 2 -1.130 -1.180 -0.8400 -0.9800 -0.9100 0.7833 0.2333 1.510
Free Cash Flow 1 -22.26 -15.62 - -11.11 - 36 12 43
FCF margin -316.3% -297.11% - -182.31% - 100.06% 46.24% 82.69%
FCF Conversion (EBITDA) - - - - - 191.37% 134.36% 116.22%
FCF Conversion (Net income) - - - - - 473.68% 295.11% 159.26%
Dividend per Share - - - - - - - -
Announcement Date 3/5/20 3/16/21 3/15/22 3/14/23 3/19/24 - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - 32.2 - 29.1 2 -
Net Cash position 1 22.4 5.58 - - - - - -
Leverage (Debt/EBITDA) - - - -2.461 x - 1.547 x 0.2239 x -
Free Cash Flow 1 -22.3 -15.6 - -11.1 - 36 12 43
ROE (net income / shareholders' equity) - - - - - - - 143%
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 - 0.9700 - -0.7900 - -0.6900 0.3600 -
Cash Flow per Share - - - - - - - -
Capex 1 0.05 0.03 0.02 - - 0.07 0.06 -
Capex / Sales 0.72% 0.65% 0.35% - - 0.19% 0.21% -
Announcement Date 3/5/20 3/16/21 3/15/22 3/14/23 3/19/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Newron Pharmaceuticals S.p.A.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
8.511 EUR
Average target price
14.84 EUR
Spread / Average Target
+74.31%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
NEWRON PHARMACEUTICALS S.P.A. Stock Newron Pharmaceuticals S.p.A.
+75.76% 170M
CSL LIMITED Stock CSL Limited
-3.79% 87.06B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+2.76% 40.25B
BIOGEN INC. Stock Biogen Inc.
-17.49% 31.09B
UCB Stock UCB
+54.63% 24.74B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-13.13% 15.91B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.12% 11.96B
INCYTE CORPORATION Stock Incyte Corporation
-15.45% 11.92B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-42.56% 11.61B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.32% 8.73B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. NWRN Stock
  4. Financials Newron Pharmaceuticals S.p.A.